Skip to main content
. Author manuscript; available in PMC: 2019 Mar 11.
Published in final edited form as: Mol Psychiatry. 2018 Aug 14:10.1038/s41380-018-0119-0. doi: 10.1038/s41380-018-0119-0

Figure 4. Pretreating panic-prone rats (chronic l-AG) with mGluR2 PAM attenuated NaLac-induced panic symptoms and facilitated extinction of fear, without affecting general locomotor activity.

Figure 4.

a) Anxiety-like behavior (as measured by reduced SI times) displayed by animals treated with 5 and 20 mg/kg i.p. of JNJ-40411813. b,c) JNJ-4041183 did not affect locomotor activity of panic-prone rats as measured by distance travelled (b) and average speed (c) during open field test. d) Bar graph demonstrating that panic-prone animals showed significant increase of social avoidance episodes. Pretreatment with 5 mg/kg or 20 mg/kg of JNJ-40411813 significantly reduced number of social avoidance episodes. *p < 0.05, compared to pre-l-AG group, #p < 0.05, compared to l-AG group. e) Heart rate response displayed by animals treated with 5 and 20 mg/kg doses of JNJ-40411813. n = 6–7 per group. Gray shading in line graphs indicates onset and duration of intravenous 0.5M NaLac infusions. #, a and bp < 0.05. f,g) Pretreating panic-prone rats with mGluR2 PAM JNJ-42153605 (20 mg/kg), did not alter acquisition of fear-induced freezing (f), but did attenuate the resistant extinction of fear-induced freezing on the recall/extinction (g). n = 5 per group. *p < 0.05, ANOVA. All data represented as mean + S.E.M.